Physician profile
Vijay S Katari
NPI 1184734733
$846.42
in general payments reported to CMS, 2019-2025
17 companies · $17.74 in 2025
The $17.74 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $130 · 2021: $317 · 2022: $319 · 2023: $62.74 · 2025: $17.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $80.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $80.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $337.95 | 2020-2022 | |
| Zimmer Biomet Holdings, INC. | $148.99 | 2022 | |
| Medtronic, INC. | $62.74 | 2023 | Ligasure |
| Kowa Pharmaceuticals America, INC. | $51.55 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $29.83 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $26.87 | 2020-2021 | |
| Dexcom, INC. | $23.34 | 2020 | |
| Eisai INC. | $19.97 | 2021 | |
| Abbott Laboratories | $19.85 | 2022 | |
| Abbvie INC. | $19.35 | 2020 | |
| Insulet Corporation | $18.70 | 2021 | |
| Exact Sciences Corporation | $17.74 | 2025 | The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $16.37 | 2021 | |
| Althera Pharmaceuticals LLC | $14.53 | 2022 | |
| Lilly USA, LLC | $13.81 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $13.00 | 2021 | |
| Ibsa Pharma INC. | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Katari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.